Literature DB >> 23914279

Pregnancy Complications and Later Development of Hypertension.

Suttira Intapad1, Barbara T Alexander.   

Abstract

Pregnancy complications such as preeclampsia and diabetes affect approximately 5 to 10 % of all pregnancies and compromise maternal and fetal health during gestation. Complications during pregnancy may also contribute to the development of hypertension and future cardiovascular risk in the mother. Moreover, fetal exposure to hypertension and diabetes during pregnancy can program hypertension and cardiovascular disease in the offspring. Transgenerational transmission of programmed cardiovascular risk highlights the importance of understanding the mechanisms that link complications during pregnancy with later hypertension in her offspring and subsequent generations. However, experimental studies are needed to investigate the cause and effect of increased blood pressure in the mother following a complicated pregnancy and provide insight into the development of preventative measures that may improve the long-term cardiovascular health of women and their offspring.

Entities:  

Keywords:  Diabetes; Fetal programming; Hypertension; Preeclampsia; Pregnancy complications; Transgenerational

Year:  2013        PMID: 23914279      PMCID: PMC3728277          DOI: 10.1007/s12170-013-0303-3

Source DB:  PubMed          Journal:  Curr Cardiovasc Risk Rep        ISSN: 1932-9520


  90 in total

1.  Soluble endoglin contributes to the pathogenesis of preeclampsia.

Authors:  Shivalingappa Venkatesha; Mourad Toporsian; Chun Lam; Jun-ichi Hanai; Tadanori Mammoto; Yeon M Kim; Yuval Bdolah; Kee-Hak Lim; Hai-Tao Yuan; Towia A Libermann; Isaac E Stillman; Drucilla Roberts; Patricia A D'Amore; Franklin H Epstein; Frank W Sellke; Roberto Romero; Vikas P Sukhatme; Michelle Letarte; S Ananth Karumanchi
Journal:  Nat Med       Date:  2006-06-04       Impact factor: 53.440

2.  Maternal and umbilical serum levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha in normal pregnancies and in pregnancies complicated by preeclampsia.

Authors:  Miğraci Tosun; Handan Celik; Bahattin Avci; Erhan Yavuz; Tayfun Alper; Erdal Malatyalioğlu
Journal:  J Matern Fetal Neonatal Med       Date:  2010-08

3.  Maternal cardiovascular impairment in pregnancies complicated by severe fetal growth restriction.

Authors:  Karen Melchiorre; George Ross Sutherland; Marco Liberati; Basky Thilaganathan
Journal:  Hypertension       Date:  2012-06-25       Impact factor: 10.190

4.  Long-term prognosis of hypertension in pregnancy.

Authors:  R Marín; M Gorostidi; C G Portal; M Sánchez; E Sánchez; J Alvarez
Journal:  Hypertens Pregnancy       Date:  2000       Impact factor: 2.108

5.  Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia.

Authors:  Carl A Hubel; Gerd Wallukat; Myles Wolf; Florian Herse; Augustine Rajakumar; James M Roberts; Nina Markovic; Ravi Thadhani; Friedrich C Luft; Ralf Dechend
Journal:  Hypertension       Date:  2007-01-08       Impact factor: 10.190

Review 6.  Gestational diabetes: implications for cardiovascular health.

Authors:  Shannon D Sullivan; Jason G Umans; Robert Ratner
Journal:  Curr Diab Rep       Date:  2012-02       Impact factor: 4.810

7.  Cardiovascular risk factors in women 10 years post early preeclampsia: the Preeclampsia Risk EValuation in FEMales study (PREVFEM).

Authors:  José T Drost; Ganiye Arpaci; Jan Paul Ottervanger; Menko Jan de Boer; Jim van Eyck; Yvonne T van der Schouw; Angela H E M Maas
Journal:  Eur J Prev Cardiol       Date:  2011-08-22       Impact factor: 7.804

8.  Lipid levels in former gestational diabetic mothers.

Authors:  C H Meyers-Seifer; B R Vohr
Journal:  Diabetes Care       Date:  1996-12       Impact factor: 19.112

9.  Postnatal modulation of prenatally programmed hypertension by dietary Na and ACE inhibition.

Authors:  Jennifer Manning; V Matti Vehaskari
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-09-30       Impact factor: 3.619

Review 10.  Mechanisms underlying developmental programming of elevated blood pressure and vascular dysfunction: evidence from human studies and experimental animal models.

Authors:  Anne Monique Nuyt
Journal:  Clin Sci (Lond)       Date:  2008-01       Impact factor: 6.124

View more
  6 in total

Review 1.  Fetal programming and cardiovascular pathology.

Authors:  Barbara T Alexander; John Henry Dasinger; Suttira Intapad
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

2.  Pregnancy Protects Hyperandrogenemic Female Rats From Postmenopausal Hypertension.

Authors:  Noha M Shawky; Chetan N Patil; Carolina Dalmasso; Rodrigo O Maranon; Damian G Romero; Heather Drummond; Jane F Reckelhoff
Journal:  Hypertension       Date:  2020-08-03       Impact factor: 10.190

Review 3.  Comprehensive understanding of developmental origins of health and disease concepts: Early intervention to non-communicable diseases in China.

Authors:  Ri-Na Su; Hui-Xia Yang
Journal:  Chronic Dis Transl Med       Date:  2015-09-29

4.  Are the blood groups of women with preeclampsia a risk factor for the development of hypertension postpartum?

Authors:  Deniz Avci; Hatice Karagoz; Ozerhan Ozer; Kubra Esmeray; Kadir Bulut; Fatma Aykas; Ali Cetinkaya; Emine Uslu; Samet Karahan; Mustafa Basak; Abdulsamet Erden
Journal:  Ther Clin Risk Manag       Date:  2016-04-19       Impact factor: 2.423

5.  Evaluating pre-pregnancy dietary diversity vs. dietary quality scores as predictors of gestational diabetes and hypertensive disorders of pregnancy.

Authors:  Selma Gicevic; Audrey J Gaskins; Teresa T Fung; Bernard Rosner; Deirdre K Tobias; Sheila Isanaka; Walter C Willett
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

6.  Maternal Blood Pressure During Pregnancy and Early Childhood Blood Pressures in the Offspring: The GUSTO Birth Cohort Study.

Authors:  Wai-Yee Lim; Yung-Seng Lee; Fabian Kok-Peng Yap; Izzudin Mohd Aris; Ngee Lek; Michael Meaney; Peter D Gluckman; Keith M Godfrey; Kenneth Kwek; Yap-Seng Chong; Seang-Mei Saw; An Pan
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.